Head-to-head
Oak Longevity vs TMates
Compared on semaglutide across the eight dimensions this database records. They differ on 6 of those eight. Oak Longevity is cheaper on all-in semaglutide at 2.4 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
Oak Longevity is $133 a month all-in for semaglutide; TMates is $249. Over twelve months that is $1,596 against $1,896. Value Scores are 95.6 and 51.8 out of 100.
Semaglutide
Plan pages: Oak Longevity plans · TMates plans
At 2.4 mg/week, Oak Longevity is $133 a month all-in and TMates is $249 — $116 apart, or $1,392 across a year. Over twelve months the totals are $1,596 (billed monthly) and $1,896 (prepaid term).
Oak Longevity charges a flat $133 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
TMates charges a flat $249 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
| Dose | Oak Longevity | Rank | TMates | Rank | Cheaper |
|---|---|---|---|---|---|
| 0.25 mg | $133 | 4/32 | $249 | 23/32 | Oak Longevity by $116 |
| 0.5 mg | $133 | 3/21 | — | — | only Oak Longevity publishes |
| 1 mg | $133 | 3/21 | — | — | only Oak Longevity publishes |
| 1.7 mg | $133 | 3/21 | — | — | only Oak Longevity publishes |
| 2.4 mg | $133 | 3/29 | $249 | 19/29 | Oak Longevity by $116 |
Oak Longevity is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 29 programs this database can rank on semaglutide, Oak Longevity sits 2 of 29 on all-in monthly cost and TMates sits 16. There are 13 other programs priced between them. The field median is $249 and the floor is $129, so both sit below the median. Oak Longevity is $4 above the cheapest semaglutide program on record. TMates is $120 above the cheapest semaglutide program on record.
NovoCare Pharmacy (Wegovy), the lowest FDA-approved semaglutide channel here, is $349 a month — Oak Longevity undercuts it by $216, TMates by $100. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | Oak Longevity | TMates | Cheaper |
|---|---|---|---|
| Month to month | $133 | $249 | Oak Longevity by $116 |
| 12-month term | — | $158 | only TMates publishes this term |
| Settled dose | Oak Longevity | TMates | Difference |
|---|---|---|---|
| 0.25 mg | $1,596 | $2,988 | $1,392 apart |
| 0.5 mg | $1,596 | — | one side unpriced |
| 1 mg | $1,596 | — | one side unpriced |
| 1.7 mg | $1,596 | — | one side unpriced |
| 2.4 mg | $1,596 | $2,988 | $1,392 apart |
Oak Longevity publishes no rate for 3-month term, 6-month term, 12-month term; TMates publishes none for 3-month term, 6-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 2.4 mg/week, the first twelve months work out to $1,596 on Oak Longevity and $2,988 on TMates. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: TMates publishes no price at 3 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 95.6 for Oak Longevity and 51.8 for TMates, against a semaglutide category floor of $129. Oak Longevity leads by 43.8 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| Oak Longevity | 67.9 | 12.8 | 10 | 5 | 95.6 |
| TMates | 36.3 | 10.5 | 0 | 5 | 51.8 |
Where the two programs differ
All-in monthly
Oak Longevity is cheaper month to month — $133 against $249, a gap of $116 every month, or $1,392 across a year if both rates hold.
Cancellation terms
Cancellation differs: Oak Longevity states Cancel before renewal, while TMates states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
Oak Longevity asks for Month-to-month; TMates asks for 12-month plan or month-to-month; substantial difference in rates. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
Oak Longevity charges one price at every dose; TMates prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Evidence status
The two prices are not equally well evidenced. Oak Longevity's figure is provider-stated and TMates's is reported. Oak Longevity rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
Twelve-month cost
Over twelve months the totals are $1,596 for Oak Longevity and $1,896 for TMates. Oak Longevity is lower by $300 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Membership fee
Neither charges a separate membership fee.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
Oak Longevity Official site
A small cash-pay telehealth program whose $133/month flat semaglutide price is currently the lowest month-to-month figure in our semaglutide index.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly itemized), so who actually makes the medication cannot be independently verified; commitment terms are Month-to-month; cancellation is Cancel before renewal; availability is stated as Availability confirmed at intake.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — First-party pricing page capture 2026-08-08
Watch: Small operator; pharmacy partner not publicly itemized. Price captured from the provider's published pages; checkout capture pending.
TMates Official site
TMates is a compounded GLP-1 telehealth service that includes medication and visits in one bundled monthly price. It offers both semaglutide and tirzepatide, with a 12-month plan that brings tirzepatide to $167/mo — the lowest committed-plan figure for tirz outside of bmiMD and NexLife.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are 12-month plan or month-to-month; substantial difference in rates; cancellation is Per provider terms; availability is stated as Confirm at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture 2026-07-14
Watch: The $158/mo (sema) and $167/mo (tirz) headline figures are 12-month plan rates; month-to-month is $249 (sema) and $297 (tirz) — some of the widest start-to-commitment spreads in the index. Reported status from RangeYourself 2026-07-14 verification.
Which molecules each one carries
Oak Longevity carries semaglutide at $133 a month; does not offer tirzepatide.
TMates carries tirzepatide at $297 a month and semaglutide at $249 a month.
Comparable only on semaglutide: they do not both publish a rankable tirzepatide price. Switching molecule mid-treatment would mean changing provider.
What neither record tells you
Oak Longevity does not publish
- no published twelve-month semaglutide rate
- no named compounding pharmacy
- no state-by-state availability list — it says Availability confirmed at intake
TMates does not publish
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no named compounding pharmacy
- no state-by-state availability list — it says Confirm at intake
- no specific cancellation or refund terms
Ask Oak Longevity and TMates for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. TMates carries a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Prepaid terms move the annual figures. TMates publishes a twelve-month rate of $158 a month against $249 month-to-month. Read those next to the cancellation terms, not the monthly rate.
Which one suits which reader
On the lowest standing monthly rate for semaglutide, Oak Longevity Official site wins this matchup. If you expect to titrate to the top of the ladder, oak longevity's flat pricing is worth more than the headline gap suggests; and if you would rather trust a better-evidenced number, oak longevity's price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. Oak Longevity's semaglutide price is provider-stated as of 2026-08-08; TMates's is reported as of 2026-07-14.
Questions
Is Oak Longevity or TMates cheaper for semaglutide?
Oak Longevity is cheaper on all-in monthly cost at 2.4 mg/week: $133 against $249, a difference of $116 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of Oak Longevity versus TMates?
Oak Longevity works out to $1,596 across twelve months and TMates to $1,896, on the plan terms each publishes.
Does Oak Longevity or TMates raise the price as the dose goes up?
Oak Longevity: no, it charges one flat rate at every dose. TMates: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do Oak Longevity and TMates differ?
6 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of Oak Longevity and TMates names its pharmacy?
Neither. Oak Longevity records Partner 503A pharmacy (not publicly itemized) and TMates records Partner 503A pharmacy (not publicly named). Without a named pharmacy, neither program's licensing or inspection history can be checked before you order.
How well evidenced are the Oak Longevity and TMates prices?
Oak Longevity's semaglutide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-08. TMates's is reported, captured 2026-07-14. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Official sources: Oak Longevity official site · TMates official site. Compounded tirzepatide and semaglutide are not FDA-approved products.